КАРДИОВАСКУЛЯРНЫЕ ФАКТОРЫ РИСКА У БОЛЬНЫХ ПОДАГРОЙ
Аннотация
Разработка концепции факторов риска стала одним из важных достижений медицины во второй половине XXвека. Главную роль в создании этой концепции сыграло Фремингемское исследование, которое позволило установить основные факторы риска атеросклероза, в том числе курение, артериальная гипертензия, дислипидемия, сахарный диабет, возраст. Вышеперечисленные факторы риска оказывают наиболее выраженное влияние на прогноз и требуют активной коррекции. Концепция факторов риска сегодня является основой как первичной, так и вторичной профилактики сердечно-сосудистых заболеваний. Тем не менее, существует еще много факторов, которые также в той или иной степени способствуют развитию атеросклероза и его осложнений. Условно их можно назвать "новыми", хотя некоторые из этих факторов риска известны уже давно. Роль подобных факторов риска в атерогенезе менее определенная и требует глубокого анализа и изучения. Следовательно, изучение таких факторов риска ишемической болезни сердца, как дисфункция эндотелия и уровень гомоцистеина в плазме крови у больных подагрой представляет большой интерес, что и явилось целью нашей работы.
Литература
Agamah, E.S. Serum uric acid and its relation to cardiovascular disease risk factors in children and young adults from a biracial community: the Bogalusa Heart Study./E.S. Agamah [et al.]//J Lab Clin Med. -1991. -Vol. 118. -P. 241-249.
Alderman, M.H. Serum uric acid and cardiovascular events in successfully treated hypertensive patients./M.H. Alderman [et al.]//Hypertension. -1999. -Vol. 34. -P. 144-150.
Alexander, R.W. Inflammation and coronary artery disease./R.W. Alexander//N Engl. J. Med. -1994. -Vol. 331. -P. 468-469.
Ashraf, M. Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusionP. an immunocytochemical study./M. Ashraf, Z.Q. Samra//J Submicrosc Cytol Pathol. -1993. -Vol.25. -P. 193-201.
Austin, R. C. Role of hyperhomocysteinemia in endothelial dysfunction and atherotrombotic disease./R.C. Austin, S.R. Lentz, G.H. Werstuck//Cell Death Differ. -2004.-Vol. 11. -P. s56-s64.
Bagnati, M. When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: a study using uric acid./M. Bagnati, C. Perugini, C. Cau.//Biochem J -1999. -Vol. 340. -P. 143-152.
Bellamy, M.F. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults./M.F. Bellamy, I.F. McDowell//Circulation. -1998.-Vol. 98. -P. 1848-1852.
Bickel, C. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease./C Bickel [et al.]//American Journal of Cardiology. -2002.-Vol. 89(1). -P. 7-12
Bonora, E. Relationship of uric acid concentration to cardiovascular risk factors in young men. Role of obesity and central fat distribution. The Verona Young Men Atherosclerosis Risk Factors Study./E. Bonora [et al.]//Int. J. Obes Relat Metab Disord. -1996. -Vol.20. -P. 975-980.
Boogaerts, M.A. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury./M.A. Boogaerts, D.E Hammerschmidt//Thromb Haemost. -1983. -Vol.50. -P. 576-580.
Culleton, B.F. Serum Uric Acid and Risk for Cardiovascular Disease and Death. The Framingham Heart Study/B.F. Culleton, M.G. Larson, W.B. Kannel, D. Levy//-1999. -Annals of Internal Medicine,?Vol. 131. -P. 8-10.
Castelli, P. Improvement of cardiac function by allopurinol in patients undergoing cardiac surgery./P. Castelli, A.M. Condemi, C. Brambillasca//J. Cardiovasc Pharmacol. -1995.-Vol. 25. -P. 119-125.
Cheng, T.T. Elevated serum homocysteine levels for gouty patients./T.T. Cheng, H.M. Lai, H.W. Chang, S.F. Luo//Clin. Rheumatol. -2005. -Vol. 24(2). -P. 103-106.
De Scheerder, I. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation./I. De Scheerder, A.M. Van de Kraay, J.M. Lamers//Am. J. Cardiol. -1991. -Vol. 68. -P. 392395.
Erdogan, D. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults.Inter./D. Erdogan [е al]//J. Clin.Practic. -2005. -Vol. 59. -P. 1276-1282.
Falasca, G.F. Superoxide anion production and phagocytosis of crystals by cultured endothelial cells./G.F. Falasca, A. Ramachandrula, K.A. Kelley//Arthritis Rheum. -1993.-Vol. 36. -P. 105-116.
Franse, L.V. Serum uric acid, its change with diuretic use and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP)./L.V. Franse, M. Pahor [et al.]//Am J Hypertension. -1999. -Vol. 12(4 Part 2). -P.13A
Fredholm, B.B. Cardiovascular effects of adenosine./B.B. Fredholm, A. Sollevi//Clin Physiol. -1986. -Vol. 6. -P. 1-21.
Freedman, D.S. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-Up Study./D.S. Freedman [et al.]//Am J Epidemiol. -1995.-Vol.141. -P.634-637.
Gonzalez-Gay, M.A. Rheumatoid arthritis: a disease associated with accelerated atherogenesis./M.A Gonzalez-Gay, C. Gonzalez-Juanatey, J. Martin//Semin Arthritis Rheum. -2005. -Vol.35. -P. 8-17.
Gutman, A.B. Views on the pathgenesis and management of primary gout./A.B. Gutman//J. Bone Joint Surg. -1972. -Vol. 54A. -P. 357-372.
Hoeschen, R.J. Oxidative stress and cardiovascular disease./R.J. Hoeschen//Can J Cardiol. -1997.-Vol.13. -P. 1021-1025.
Hyon, K. C. Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease./K. C. Hyon, G. Curhan//Circulation. -2007.-Vol.116. -P.894-900.
Istok, R. Total plasma homocysteine in patients with gout./R. Istok, M. Kovalancik, J. Rovensky//J. Rheumatol. -1999. -Vol. 26(9). -P. 2068-2069.
Janssens, H.J. Gout, just a nasty event or a cardiovascular signal? A study from primary care./H.J. Janssens [et al.]//Family Practice -2003.-Vol. 20. -P. 413-416.
Kato, M. Status of endothelial dependent vasodilation in patients with hyperuricemia./M. Kato, I. Hisatome, Y. Tomikura//Am J Cardiol. -2005. -Vol. 96(11). -P. 1576-1578.
Kogure, K. Evaluation of serum uric acid changes in different forms of hepatic vascular inflow occlusion in human liver surgeries./K. Kogure, M. Ishizaki//Life Sci. -1999. -Vol. 64. -P. 305-313.
Krishnan, E. Gout and the risk of acute myocardial infarction./E. Krishnan, J.F. Baker, D.E. Furst, H. R. Schumacher//Arthritis Rheum. -2006. -Vol. 54. -P. 2688-2696.
Krishnan, E. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis./E. Krishnan, V.B. Lingala, G. Singh//Circulation. -2004. -Vol. 110. -P. 1774-1779.
Kroll, K. Capillary endothelial transport of uric acid in guinea pig heart./K. Kroll, T.R. Bukowski, L.M. Schwartz//Am J Physiol. -1992. -Vol. 262. -P. H420-H431.
Li, D. Relationship between serum uric acid and selected cardiovascular risk factors in Hangzhou populations Songklanakarin./D. Li, X. Yu, S. Siriamornpun//J. Sci. Technol. -2006.-Vol.28(Suppl. 1). -P.133-137.
Liese, A.D. Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases./A.D. Liese [et al.]//Epidemiology. -1999. -Vol. 10. -P. 391-397.
Raatikainen, M. J. Contribution of endothelium and cardiomyocytes to hypoxia-induced adenosine release./M.J. Raatikainen [et al.]//J. Mol. Cell Cardiol. -1994. -Vol.26. -P. 1069-80.
Reunanen, A. Hyperuricemia as a risk factor for cardiovascular mortality./A. Reunanen [et al.]//Acta Med Scand Suppl. -1982.-Vol. 668. -P.49-59.
Schlotte, V. Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro./V. Schlotte, A. Sevanian, P. Hochstein, K.U. Weithmann//Free Rad Biol Med. -1998. -Vol.25. -P.839-47.
Skinner, K.A. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor./K.A. Skinner [et al.]//J Biol Chem. -1998.-Vol.273. -P.24491-7.
The Coronary Drug Project Research Group. Serum uric acid: its association with other risk factors and with mortality in coronary heart disease. J Chron Dis. -1976.-Vol.29. -P.557-69.
Tiong, A.Y. Inflammation and coronary artery disease./A.Y. Tiong, D. Brieger//Am Heart J. -2005.-Vol.150. -P.11-8.
Tsutsumi, Z. Total plasma homocysteine is not increased in Japanese patients with gout./Z. Tsutsumi [et al.]//J Rheumatol. -2002. -Vol.29(8). -P. 1805-6.
Wannamethee, S.G. Serum urate and the risk of major coronary heart disease events./S.G. Wannamethee [et al.]//Heart. -1997. -Vol.78. -P. 147-53.
Webb, D.J. The pharmacology of human blood vessels in vivo./D.J. Webb//J Vasc Res. -1995. -Vol.32. -P.2-15.
Zhang, C. Homocysteine induces programmed cell death in human vascular endothelial cell throw activation of the unfoulded protein response/C. Zhang [et al.]//J. Biol. Chem. -2001. -Vol.276. -P. 35867-35874
Zweier, J.L. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues./J.L. Zweier [et al.]//Proc Natl Acad Sci U S A. -1988.-Vol.85. -P. 4046-4050.
Ильиных, Е. В. Факторы риска развития кардиоваскулярных заболеваний у больных подагрой: автореф. дис.. канд. мед. наук: 14.00.39/Е. В. Ильиных; Рос. мед. ун-т. -М., 2006. -21 с.
